Revenue:
$6.5 million (down from $14.7 million in Q1 2025)
Net loss:
$117.5 million (improved from $202.5 million in Q1 2025)
Cash position:
$665.2 million as of March 31, 2026
R&D expenses:
$87.9 million (down from $129.6 million)
G&A expenses:
$34.6 million (down from $54.7 million)
Net cash used in operations:
$81.1 million (improved from $132.0 million)
2026 operational cash burn guidance:
less than $390 million
Cash runway:
into early 2028
Pipeline advances include Phase 1/2 DAHLIA study early data and AI-derived oncology programs
Reported May 6, 2026